Announcements Trials
Browse Landscape

Phase

Phase 1 27Phase 2 22Phase 1/2 15Phase NA 1Phase EARLY_PHASE1 1Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Recurrence 4Multiple Myeloma 4Lymphoma 4Ovarian Neoplasms 3Burkitt Lymphoma 3Neoplasms, Plasma Cell 2Nasopharyngeal Carcinoma 2Lymphoma, T-Cell 2Leukemia, Myeloid, Acute 2Solid Tumors 1Solid Tumor 1Solid Cancer 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 1POEMS Syndrome 1Neuromyelitis Optica 1Neuroblastoma 1Neoplasms, Neuroepithelial 1Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Myositis 1Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease 1Myasthenia Gravis 1Multiple Sclerosis 1Metastatic Castration-resistant Prostate Cancer 1Melanoma 1Lymphoma, Mantle-Cell 1

Interventions

Nivolumab 9pembrolizumab 6Ipilimumab 5Magnetic Resonance Spectroscopy 3resiquimod 2encorafenib 2binimetinib 2aldesleukin 2Oncolytic Virotherapy 2MART-1 Antigen 2Interleukin-2 2Cyclophosphamide 2urelumab 1tremelimumab 1tetraethylpyrazine 1technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1relatlimab 1montanide ISA 51 1glucopyranosyl lipid-A 1fludarabine phosphate 1fludarabine 1durvalumab 1clevudine 1cemiplimab 1avelumab 1Specimen Handling 1Sentinel Lymph Node Biopsy 1S 28463 1Radiotherapy 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Melanoma × fludarabine × Clear all
NCT02652455 2025-08-19

Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Completed
11 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡